ODDITY Tech Ltd.

Good afternoon, and welcome to Audity's second quarter 2023 earnings conference call. At this time, I'd like to turn the conference over to Maria Licoris, Investor Relations for Audity. Thank you. You may begin.

Thank you, Operator. I'm joined by Aran Holtzman, Audity co-founder and CEO, and Lindsay Druckerman, Audity's global CFO. Hello. As a reminder, due to the timing of this earnings call, which is within the 25-day quiet period following the company's IPO, we will not be taking questions on today's call. Management's remarks on this call that do not concern past events are forward-looking statements. These may include predictions, expectations, or estimates, including statements about Audity's business strategy, market opportunity, future financial performance, and potential long-term success. Forward-looking statements involve risks and uncertainties, and actual results could differ materially due to a variety of factors. These factors are described under forward-looking statements in our earnings press release and in our prospectus filed with the Securities and Exchange Commission on July 18, 2023. We do not undertake any obligation to update forward-looking statements, which speak only as of today. Finally, during this call, we will discuss certain non-GAAP financial measures which we believe are useful supplemental measures for understanding our business. Definitions and reconciliations of these non-GAAP financial measures to their most comparable GAAP measures are included in our earnings press release we issued today. I will now hand the call over to Oran.

Thank you, everyone, for joining us today. We are very excited to share our second quarter results, and our first earning call as a public company. And it's only fitting that we kick off our lives as a public company with an outstanding quarter of financial performance that position us to raise our 2023 outlook for revenue and profit above our plan. We generated $151 million of net revenue, a 55% increase from last year, and $42 million of adjusted EBITDA in the second quarter, representing 27.6% of adjusted EBITDA margin. These results are above the estimates we issued in our IPO across every metric, including sales, adjusted EBITDA, and net income. We are making very strong progress in our mission to transform the global beauty and wellness market with technology and entrepreneurial DNA, and we are here to build something huge. Our technology-powered platform is unlocking online for massive and super attractive time by leveraging data science, artificial intelligence, computer vision, and now biotech to deliver superior products and experiences to our more than 40 million users. Our model has rapidly scaled to what we believe is the largest and most profitable online direct-to-consumer platform in the industry. With our existing powerhouse brand, Illmakiyajit spoiled child today and brands three and four in development to launch in the future. In order to perform successfully online only, we're investing heavily in data science and technology early on and built our tech team to be the largest team in the company. Technology continues to be the primary investment priority for us today, although we believe we are already way ahead of our competitors. We achieved many important milestones during the second quarter that we believe set us up for a long runway of top and bottom line growth. First, we made significant progress in the quarter, which include driving revenue growth and market share gains for our Ilmak Yazid's Paul Child brands, expanding our existing brands into new categories, and continuing to develop new brands tailored for our user base, which will be connected to the ODP D2C platform. Second, the acquisition of Revela and launch of Audity Labs was a game-changing achievement for us during this quarter. We moved aggressively to use pharma-grade AI technology to boost the development and expansion of proprietary science-backed molecules and product formulation. We believe Audity Labs will change the industry and will be a massive driver for Audity as a company. And finally, With a successful completion of our IPO, we recruited best-in-class investor partners to join us, building a truly transformational business that compounds long-term value. Moving on to our business performance, net revenue increased 55% in the second quarter, driven by growth across brands, product categories, and markets. The unprecedented success of Spoiled Child is a compelling proof point of the power of our model and tech platforms. Spoiled Child scaled to $50 million of order billings in the first 12 months, which we believe makes it the most successful direct-to-consumer brand launch across any vertical. The brand became profitable only one year after launch, and it will be a nice contributor to EBITDA this year. Spoiled Child continues to look better than Il Makiage in all metrics, although Il Makiage is one of the strongest D2C brands in history in terms of scale, growth, and profitability. Yet, Spoiled Child looks even stronger. Drilling into physical products, new launches were a solid driver of results in the quarter, and it's a compelling engine for us into 2023 and beyond. We have an exciting product roadmap across color, skin, and hair for the rest of 2023 and 2024. Our data-driven approach and direct-to-consumer model gives us the powerful advantage of testing products in markets and gathering data before officially launching to increase our chances of success. We truly launch products for our user base, unlike other D2C companies who launch products and then search for an audience for it. We already have live in-market tests that we launch during Q2 for our 2024 launches with very encouraging initial signs. We are also making a rapid progress on product development based on our proprietary and patented pending ODP Labs molecules, which I will elaborate shortly. On technology products, we continue to build and optimize our AI and machine learning models to enable profitable growth and support the user journey. We made continued progress on our various models that improve repeat rate. We continue to roll out new versions of PowerMatch and Spoiled Brain to enhance product recommendation. Introducing improved post-purchase models that drive higher AOP, improving economics for first purchase and lifetime revenue. We continue to build our generative AI capabilities in text, images, video, and audio. We test across range of use cases, including customer acquisition and retention. We continue to make very rapid and meaningful progress in computer vision. Our strong team of computer vision scientists and patent and vision technology has massive potential for our future. We continue to prioritize focus on two fronts. First, enhancing our existing technology products, and second, building new vision tools to deliver groundbreaking diagnostic capabilities. In the second quarter, we delivered progress in both of those fronts. We continued integration of vision technology into our existing AI matching engine. We made significant progress in the quarter in our new vision tools to both identify and categorize individual skin issues. These are central capabilities we are building to support the roll-off of brand number three with additional cases for the future. On the marketing front, we continue to achieve very strong efficiency on marketing spend, supporting our attractive revenue growth and strong profitability. We continue to optimize our performance marketing distribution model, and we continue to optimize our ads and conversion funders based on high-quality data sets. We additionally continue to invest in our brand to drive awareness. For Il Makiage, our close partnership with the Arsenal Women's Football Club was recognized as one of the most successful women's sports partnerships in the UK. As for Spoiled Child, we launched our first TV campaign, which reached over 50 million households, delivered over 260 million impressions, which helped increase brand awareness. Moving to Audity Labs, we closed the acquisition of Revela in April to bring true biotech capabilities and pharma's AI-based medical discovery to drive game-changing physical product innovation to our category. From day one, we worked to harness these capabilities to drive the next generation of physical product innovation. We stood up Audity Labs, opening our research lab in Kendall Square, Boston, and expanding our team of the highest caliber bioengineers, chemists, and PhD scientists. The lab is fully operating today with our scientists working hard on our future. The lab is being overseen by myself, by Dr. Evan Zhao, and by Dr. David Zhang. We are deep in the works on over 10 new molecules to address pressing user pain points and unlock new and massive terms for auditing. Finally, we made a very strong progress on our future brand launches, including brand number three and brand number four, which are planned to go live in 2025. For brand three, the current stage is mainly around continued effort of developing our computer vision technology that will be the core of the brand. In addition, we make progress in product development. My sister and I are spending at least 20% of our time on building brand number three. As for brand number four, we picked the category for the brand, and we have started building a strong team and began working on brand positioning within the category. With that, let me hand it to Lindsay Brockerman, our CFO, to review our financial performance and outlook.